The FDA has approved a new version of the inhalable FluMist that can be kept refrigerated instead of frozen. The regulatory approval is a notable win for the manufacturer, MedImmune, which has been confounded by difficulties in developing a market for the flu vaccine. MedImmune expects that the refrigerated reformulation will make it easier to keep the vaccine on hand and boost sales. The new vaccine will be available in August for the coming flu season.
- check out MedImmune's release on the approval
- here's the UPI's report on the approval
Related Articles:
MedImmune investor urges company to seek bidders. Report
MedImmune gets nod for new vaccine tech. Report
MedImmune touts new FluMist version. Report